Maximilian Niyazi1, Sebastian Adeberg2, David Kaul3, Anne-Laure Boulesteix4, Nina Bougatf2, Daniel F Fleischmann5, Arne Grün3, Anna Krämer6, Claus Rödel6, Franziska Eckert6, Frank Paulsen7, Kerstin A Kessel8, Stephanie E Combs8, Oliver Oehlke9, Anca-Ligia Grosu9, Annekatrin Seidlitz10, Annika Lattermann10, Mechthild Krause11, Michael Baumann10, Maja Guberina12, Martin Stuschke12, Volker Budach3, Claus Belka5, Jürgen Debus13. 1. Department of Radiation Oncology, University Hospital, LMU Munich, Germany; German Cancer Consortium (DKTK), partner sites Munich, Heidelberg, Berlin, Frankfurt, Tübingen, Freiburg, Dresden, Essen; and German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: maximilian.niyazi@med.uni-muenchen.de. 2. German Cancer Consortium (DKTK), partner sites Munich, Heidelberg, Berlin, Frankfurt, Tübingen, Freiburg, Dresden, Essen; and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiation Oncology, University of Heidelberg, Germany; Heidelberg Institute for Radiation Oncology (HIRO), Germany. 3. German Cancer Consortium (DKTK), partner sites Munich, Heidelberg, Berlin, Frankfurt, Tübingen, Freiburg, Dresden, Essen; and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiation Oncology, Charité-University Hospital Berlin, Germany. 4. Institute for Medical Information Processing, Biometry and Epidemiology, University of Munich, Germany. 5. Department of Radiation Oncology, University Hospital, LMU Munich, Germany; German Cancer Consortium (DKTK), partner sites Munich, Heidelberg, Berlin, Frankfurt, Tübingen, Freiburg, Dresden, Essen; and German Cancer Research Center (DKFZ), Heidelberg, Germany. 6. German Cancer Consortium (DKTK), partner sites Munich, Heidelberg, Berlin, Frankfurt, Tübingen, Freiburg, Dresden, Essen; and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiation Oncology, University Hospital Johann Wolfgang Goethe University, Frankfurt, Germany. 7. German Cancer Consortium (DKTK), partner sites Munich, Heidelberg, Berlin, Frankfurt, Tübingen, Freiburg, Dresden, Essen; and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiation Oncology, Faculty of Medicine and University Hospital Tübingen, Eberhard Karls University Tübingen, Germany. 8. German Cancer Consortium (DKTK), partner sites Munich, Heidelberg, Berlin, Frankfurt, Tübingen, Freiburg, Dresden, Essen; and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Germany. 9. German Cancer Consortium (DKTK), partner sites Munich, Heidelberg, Berlin, Frankfurt, Tübingen, Freiburg, Dresden, Essen; and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiation Oncology, University Medical Center Freiburg, Germany. 10. German Cancer Consortium (DKTK), partner sites Munich, Heidelberg, Berlin, Frankfurt, Tübingen, Freiburg, Dresden, Essen; and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Germany. 11. German Cancer Consortium (DKTK), partner sites Munich, Heidelberg, Berlin, Frankfurt, Tübingen, Freiburg, Dresden, Essen; and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Germany; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology - OncoRay, Dresden, Germany; National Center for Tumor Diseases (NCT), partner site Dresden, Germany. 12. German Cancer Consortium (DKTK), partner sites Munich, Heidelberg, Berlin, Frankfurt, Tübingen, Freiburg, Dresden, Essen; and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiotherapy, University of Duisburg-Essen, University Hospital Essen, Germany. 13. German Cancer Consortium (DKTK), partner sites Munich, Heidelberg, Berlin, Frankfurt, Tübingen, Freiburg, Dresden, Essen; and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiation Oncology, Heidelberg Ion Therapy Center (HIT), Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany.
Abstract
BACKGROUND AND PURPOSE: Reirradiation (reRT) is a valid option with considerable efficacy in patients with recurrent high-grade glioma, but it is still not known which patients might be optimal candidates for a second course of irradiation. This study validated a newly developed prognostic score independently in an external patient cohort. MATERIAL AND METHODS: The reRT risk score (RRRS) is based on a linear combination of initial histology, clinical performance status, and age derived from a multivariable model of 353 patients. This score can predict post-recurrence survival (PRS) after reRT. The validation dataset consisted of 212 patients. RESULTS: The RRRS differentiates three prognostic groups. Discrimination and calibration were maintained in the validation group. Median PRS times in the development cohort for the good/intermediate/poor risk categories were 14.2, 9.1, and 5.3 months, respectively. The respective groups within the validation cohort displayed median PRS times of 13.8, 8.8, and 3.8 months, respectively. Uno's C for development data was 0.64 (CI: 0.60-0.69) and for validation data 0.63 (CI: 0.58-0.68). CONCLUSIONS: The RRRS has been successfully validated in an independent patient cohort. This linear combination of three easily determined clinicopathological factors allows for a reliable classification of patients and may be used as stratification factor for future trials.
BACKGROUND AND PURPOSE: Reirradiation (reRT) is a valid option with considerable efficacy in patients with recurrent high-grade glioma, but it is still not known which patients might be optimal candidates for a second course of irradiation. This study validated a newly developed prognostic score independently in an external patient cohort. MATERIAL AND METHODS: The reRT risk score (RRRS) is based on a linear combination of initial histology, clinical performance status, and age derived from a multivariable model of 353 patients. This score can predict post-recurrence survival (PRS) after reRT. The validation dataset consisted of 212 patients. RESULTS: The RRRS differentiates three prognostic groups. Discrimination and calibration were maintained in the validation group. Median PRS times in the development cohort for the good/intermediate/poor risk categories were 14.2, 9.1, and 5.3 months, respectively. The respective groups within the validation cohort displayed median PRS times of 13.8, 8.8, and 3.8 months, respectively. Uno's C for development data was 0.64 (CI: 0.60-0.69) and for validation data 0.63 (CI: 0.58-0.68). CONCLUSIONS: The RRRS has been successfully validated in an independent patient cohort. This linear combination of three easily determined clinicopathological factors allows for a reliable classification of patients and may be used as stratification factor for future trials.
Authors: T Gupta; M Maitre; P Maitre; J S Goda; R Krishnatry; A Chatterjee; A Moiyadi; P Shetty; S Epari; A Sahay; V Patil; R Jalali Journal: Clin Transl Oncol Date: 2021-02-02 Impact factor: 3.405
Authors: Norbert Galldiks; Maximilian Niyazi; Anca L Grosu; Martin Kocher; Karl-Josef Langen; Ian Law; Giuseppe Minniti; Michelle M Kim; Christina Tsien; Frederic Dhermain; Riccardo Soffietti; Minesh P Mehta; Michael Weller; Jörg-Christian Tonn Journal: Neuro Oncol Date: 2021-06-01 Impact factor: 12.300
Authors: Rainer J Klement; Ilinca Popp; David Kaul; Felix Ehret; Anca L Grosu; Bülent Polat; Reinhart A Sweeney; Victor Lewitzki Journal: J Neurooncol Date: 2021-12-23 Impact factor: 4.130